Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment ...

Background Comorbidities add complexity to pulmonary arterial hypertension (PAH), but also open opportunities to use therapies with benefits beyond the cardiovascular (CV) system, particularly ...

PMA submission targeted for May 29, 2026 in alignment with FDAVantive commits to additional funding support ahead of PMA acceptance milestone ...

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in ...

Longevity, the length of human life, is the subject of growing scientific and commercial interest. Click here to read more.

Objectives Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) are associated with improved ...

Every year, hundreds of thousands of men receive a prostate cancer diagnosis and immediately face a decision that medical textbooks present as relatively binary: remove the entire prostate gland or ...

Overall survival improved with relacorilant plus nab-paclitaxel (HR 0.65), delivering a 4.1-month median gain at 76% maturity. Consistency was observed regardless of taxane-free interval (≤6 months HR ...

Background Artificial intelligence ECG (AI-ECG) models can predict cardiovascular outcomes, but their clinical adoption is limited by restricted access to training data and uncertain generalisability.

1 Department of Cardiovascular Surgery, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, National Centre for Cardiovascular Diseases, Beijing, China 2 National ...

Positive results from the EMERALD-3 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with IMJUDO® (tremelimumab-actl), lenvatinib and transarterial chemoembolization (TACE), ...